Clinical Trials

Sponsor: MUSC

Sponsor Study ID: 103352

Study Title: Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial

NCT Number: NCT05036226

Phase: I/II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Larynx, Other Female Genital, Prostate

Study Objectives: Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.

For more information about the trial above please contact the study team:

Principal Investigator, Michael Lilly, at lillym@musc.edu.
Study Coordinator, Lindsay Hunt, at winterl@musc.edu, or please call +1 843-792-9778.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)